Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda

Lancet Infectious Diseases

Volumn 2, Issue 8, 2002, Pages 494-501

  Guerin, Philippe J ^a,c   Olliaro, Piero ^b,c   Sundar, Shyam ^d   Boelaert, Marleen ^e   Croft, Simon L ^f   Desjeux, Philippe ^b   Wasunna, Monique K ^g   Bryceson, Anthony D M ^f  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d BANARAS HINDU UNIVERSITY   (India)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; VACCINE;

CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; DRUG COST; DRUG FORMULATION; HEALTH CARE COST; HUMAN; INCIDENCE; INDIA; INFECTION CONTROL; INFECTION RISK; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VECTOR CONTROL; VISCERAL LEISHMANIASIS;

EID: 0036319712     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00347-X     Document Type: Note

References (76)

1. Human leishmaniases: Epidemiology and public health aspects
2. Leishmaniasis. Public health aspects and control
3. Socio-economics of visceral leishmaniasis in Bihar (India)
4. The re-emergence of visceral leishmaniasis in Brazil
5. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: Course and impact from 1984 to 1994
6. Leishmaniasis
7. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya
8. Malnutrition as a risk factor for severe visceral leishmaniasis
9. Leishmania and human immunodeficiency virus coinfection: The first 10 years
10. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
11. Leishmania and HIV in gridlock
12. HIV-associated visceral leishmaniasis
13. Endemic disease and development: The leishmaniases
14. The global burden of disease in 1990: Summary results, sensitivity analysis and future directions
15. Visceral leishmaniasis control in India through primary health care system: A successful experiment of district level planning
16. Epidemiology of visceral leishmaniasis in India
17. Decreased sensitivity to meglumine antimoniate (Glucantime) of leishmania infantum isolated from dogs after several courses of drug treatment
18. Protective efficacy of lambdacyhalothrin-impregnated bednets against Phlebotomus orientalis, the vector of visceral leishmaniasis in Sudan
19. Laboratory evaluation of lambda-cyhalothrin a microencapsulated formulation on mosquito nets for control of vector mosquitos
20. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan
21. Leishmaniasis
22. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis
23. Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis
24. Rapid accurate field diagnosis of Indian visceral leishmaniasis
25. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis
26. Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children
27. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1
28. Diagnostic lag period in kala-azar: Test for early diagnosis needed
29. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
30. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate)
31. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate
32. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya
33. Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
34. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
35. Clinical and experimental advances in treatment of visceral leishmaniasis
36. Current issues in the treatment of visceral leishmaniasis
37. Drug resistance in Indian visceral leishmaniasis
38. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
39. Practical guide for the treatment of leishmaniasis
40. Visceral leishmaniasis unresponsive to antimonial drugs: I, clinical and immunological studies
41. Investigation of the spread of human visceral leishmaniasis in central Tunisia
42. Comparison of regimens of amphotericin B deoxycholate in kala-azar
43. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
44. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
45. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial
46. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis
47. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion
48. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
49. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
50. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients
51. Developments in the treatment of leishmaniasis and trypanosomiasis
52. A harvest not yet reaped: Genomics to new drugs in leishmania and trypanosomes
53. Drug development for neglected diseases: A deficient market and a public-health policy failure
54. Trial of oral miltefosine for visceral leishmaniasis
55. Oral treatment of visceral leishmaniasis with miltefosine
56. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
57. A policy for leishmaniasis with respect to the prevention and control of drug resistance
58. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine): An open-label randomized phase-II clinical study
59. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
60. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources
61. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom
62. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycin)-antimonial combinations, a pilot study in Bihar, India
63. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: A randomized dose-finding clinical trial
64. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis
65. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
66. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi
67. Diagnostic PCR with Leishmania donovani specificity
68. Operational validation of the direct agglutination test for diagnosis of visceral leishmaniasis
69. Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis
70. Direct agglutination test for early diagnosis of Indian visceral leishmaniasis
71. Evaluation of the direct agglutination test (DAT) using freeze-dried antigen for the detection of anti-Leishmania antibodies in stored sera from various patient groups in Ethiopia
72. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: Experience from the Sudan
73. Short report: Detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis